Prosecution Insights
Last updated: November 04, 2026
Application No. 19/014,002

COMPOSITIONS FOR TOPICAL TREATMENT OF MICROBIAL INFECTIONS

Non-Final OA §102§DOUBLEPATENT
Filed
Jan 08, 2025
Priority
Apr 20, 2012 — provisional 61/636,203 +4 more
Examiner
MCMILLIAN, KARA RENITA
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hennepin Life Sciences LLC
OA Round
1 (Non-Final)
31%
Grant Probability
At Risk
1-2
OA Rounds
1y 10m
Est. Remaining
69%
With Interview

Examiner Intelligence

Grants only 31% of cases
31%
Career Allowance Rate
304 granted / 983 resolved
-29.1% vs TC avg
Strong +38% interview lift
Without
With
+37.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
55 currently pending
Career history
1056
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
47.6%
+7.6% vs TC avg
§102
10.1%
-29.9% vs TC avg
§112
17.7%
-22.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 983 resolved cases

Office Action

§102 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Priority This application is a Continuation of U.S. Application No. 15/727,772 filed on 10/09/2017, now U.S. Patent No. 12,194,140; which is a Continuation of U.S. Application No. 15/056,239 filed on 02/29/2016, now U.S. Patent No. 11,786,454; which is a Division of U.S. Application No.13/866,722 filed on 04/19/2013, now U.S. Patent No. 9,724,295; which claims benefit to U.S. Provisional No. 61/650,755 filed on 05/23/2012 and U.S. Provisional No. 61/636,203 filed on 04/20/2012. Response to Amendment Applicant’s preliminary amendment filed on May 27, 2025 cancelling claims 2-20 has been entered. Claim 1 is currently pending. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-17 of U.S. Patent No. 12,194,140 (Provided on IDS dated May 27, 2025). Although the claims at issue are not identical, they are not patentably distinct from each other because the cited claims of the instant application and the cited claims of ‘140 are substantially overlapping in scope for the following reasons: Claim 1 of the instant application claims a topical cream, gel, or foam composition comprising an effective amount of glycerol monolaurate and at least one cellulose derivative. Claims 1-17 of ‘140 claim a topical composition comprising an effective amount of glycerol monolaurate (GML) and a non-aqueous gel comprised of at least one cellulose derivative, wherein the non-aqueous gel is at a concentration of about 10% to about 25% of the composition, wherein the composition has a pH in a range of about 4-5.5, wherein the at least one cellulose derivative is one or more of hydroxyethyl cellulose, hydroxypropyl cellulose, methylcellulose, ethyl cellulose, hydroxypropyl methyl cellulose, or cellulose acetate, and wherein the GML is present at a concentration of about 10 μg/mL to about 100 mg/mL in the composition; and wherein the GML is the isomer of GML with lauric acid in the 2-position of glycerol. Thus the cited claim of the instant application would be anticipated by the claims of ‘140 which claim a topical gel composition comprising an effective amount of glycerol monolaurate and at least one cellulose derivative. Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-10 of U.S. Patent No. 11,786,454 (Provided on IDS dated May 27, 2025). Although the claims at issue are not identical, they are not patentably distinct from each other because the cited claims of the instant application and the cited claims of ‘454 are substantially overlapping in scope for the following reasons: Claim 1 of the instant application claims a topical cream, gel, or foam composition comprising an effective amount of glycerol monolaurate and at least one cellulose derivative. Claims 1-10 of ‘454 claim the use of a composition comprising GML and a non-aqueous gel comprised of a combination of propylene glycol, polyethylene glycol, and a cellulose derivative and the non-aqueous gel having a pH from about 4.0 to about 4.5, wherein the non-aqueous gel is at a concentration of about 10% to about 25% of the composition, wherein GML is present at a concentration of about 10 μg/mL to about 100 mg/mL; and wherein the GML is the isomer of GML with lauric acid in the 2-position of glycerol. Thus the cited claim of the instant application would be anticipated by the claims of ‘454 which includes a topical gel composition comprising an effective amount of glycerol monolaurate and at least one cellulose derivative. This rejection is being made since Applicant designates this application as a continuation of U.S. Application No. 15/056,239 filed on 02/29/2016, now U.S. Patent No. 11,786,454. Please note that in order to obtain the benefit of the prohibition of nonstatutory double patenting rejection under 35 U.S.C. 121, claims must be formally entered, restricted in, and removed from an earlier application and filed in divisional application only. The U.S. Court of Appeals for the Federal Circuit has concluded that the protection of 35 U.S.C. 121 does not extend to all types of continuing applications, stating that "the protection afforded by section 121 to applications (or patents issued therefrom) filed as a result of a restriction requirement is limited to divisional applications." Pfizer, Inc. v. Teva Pharmaceuticals USA, Inc., 518 F.3d 1353, 1362, 86 USPQ2d 1001, 1007-1008 (Fed. Cir. 2008). Claim 1 is rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-15 of U.S. Patent No. 9,724,295 (Provided on IDS dated May 27, 2025). Although the claims at issue are not identical, they are not patentably distinct from each other because the cited claims of the instant application and the cited claims of ‘295 are substantially overlapping in scope for the following reasons: Claim 1 of the instant application claims a topical cream, gel, or foam composition comprising an effective amount of glycerol monolaurate and at least one cellulose derivative. Claims 1-15 of ‘295 claim a composition comprising glycerol monolaurate, propylene glycol at a concentration of about 65% (w/w) to about 80% (w/w), polyethylene glycol at a concentration of about 20% (w/w) to about 35% (w/w), and a cellulose derivative. Thus the cited claim of the instant application would be anticipated by the claims of ‘295 which claim a topical gel composition comprising an effective amount of glycerol monolaurate and at least one cellulose derivative. Claim 1 is provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-5 of copending Application No. 18/562,917 (U.S. Publication No. 2024/0269102 A1). Although the claims at issue are not identical, they are not patentably distinct from each other because the cited claims of the instant application and the cited claims of copending ‘917 are substantially overlapping in scope for the following reasons: Claim 1 of the instant application claims a topical cream, gel, or foam composition comprising an effective amount of glycerol monolaurate and at least one cellulose derivative. Claims 1-5 of copending ‘917 claim a biological active composition comprising 15-30% (w/v) glycerol monolaurate (GML) in a non-aqueous gel and one or more accelerants, wherein at least one of the one or more accelerants is selected from: an organic acid, a chelator, an antibacterial agent, an antifungal agent, an antiviral agent, an antiprotozoan, or a combination thereof wherein the non-aqueous gel comprises hydroxypropyl cellulose or hydroxyethyl cellulose. Thus the cited claim of the instant application would be anticipated by the claims of copending ‘917 which claim a topical gel composition comprising an effective amount of glycerol monolaurate and at least one cellulose derivative. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States. Claim 1 is rejected under pre-AIA 35 U.S.C. 102(b) as being anticipated by Epstein U.S. Patent No. 5,906,814 (Provided on IDS dated May 27, 2025). Claim 1 of the instant application claims a topical cream, gel, or foam composition comprising an effective amount of glycerol monolaurate and at least one cellulose derivative. Epstein discloses topical film-forming compositions comprising a non-toxic volatile solvent, a cellulosic material, an esterification agent, a glycerol monolaurate crosslinking agent, and various medicinal antibiotic, antifungal, anesthetic, analgesic and virucidal agents (abstract). Epstein teaches that the cellulosic materials applicable include hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, dextran, guaran, resin Jalap, and mixtures thereof, wherein a particularly preferred material is a hydroxypropyl cellulose (KLUCEL HF) (column 2 lines 45-54). Claims 1-6 of Epstein specifically claim the use of a topical film-forming composition comprising a non-toxic volatile solvent such as ethyl alcohol, isopropyl alcohol, methyl alcohol and combinations thereof; a cellulosic material such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, and combinations thereof, in an amount of 0.1 to 2.5 weight percent; an esterification agent; and glycerol monolaurate in an amount of about 0.1 to 8 weight percent. Epstein specifically discloses topical gel compositions which anticipate claim 1 of the instant application since Gels A-D comprise either 0.5 or 5.0 wt. percent of GML; and between 1.5 and 1.9 wt. percent of hydroxypropyl cellulose (Table 1 in columns 7 and 8). Thus the cited claim of the instant application is anticipated by Epstein. Claim 1 is rejected under pre-AIA 35 U.S.C. 102(b) as being anticipated by Scholz et al. U.S. Publication No. 2005/0058673 A1 (Provided on IDS dated May 27, 2025). Claim 1 of the instant application claims a topical cream, gel, or foam composition comprising an effective amount of glycerol monolaurate and at least one cellulose derivative. Scholz et al. specifically discloses a composition which anticipates claim 1 in Table 16a on page 35 of Scholz et al. Example No. 47 comprises 1.00 wt. % GML (glycerol monolaurate), and 2.08 wt. % NATROSOL plus type (cetyl hydroxyethyl cellulose see Glossary of components [0262] pages 25-26), thus anticipating the cited claim which claims a topical gel composition which comprises GML, and at least one cellulose derivative. Thus the cited claim of the instant application is anticipated by Scholz et al. Conclusion Claim 1 is rejected. Claims 2-20 are cancelled. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KARA R. MCMILLIAN whose telephone number is (571)270-5236. The examiner can normally be reached Tuesday-Friday 12:00 PM-6:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam C. Milligan can be reached at (571)270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KARA R. MCMILLIAN/Primary Examiner, Art Unit 1623 KRM
Read full office action

Prosecution Timeline

Jan 08, 2025
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §102, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12733640
ANTIMICROBIAL FERULIC ACID DERIVATIVES AND USES THEREOF
2y 5m to grant Granted Sep 15, 2026
Patent 12728121
COMPOSITIONS AND METHODS FOR TREATING IDIOPATHIC PULMONARY FIBROSIS
5y 1m to grant Granted Sep 08, 2026
Patent 12714697
BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS
1y 1m to grant Granted Aug 25, 2026
Patent 12698286
COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF
4y 7m to grant Granted Aug 04, 2026
Patent 12637467
INHIBITOR OF BTK AND MUTANTS THEREOF
4y 9m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
31%
Grant Probability
69%
With Interview (+37.9%)
3y 8m (~1y 10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 983 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month